well, with her youngest child developing of symptoms of an inflammatory polyarthritis aged four years old. He went on to have a genetic testing for a mutation in the NOD2 gene which led to a diagnosis of Blau syndrome. Following her sons diagnosis of Blau syndrome this patient's original diagnosis of SJIA was revisited. Blausyndromeis anautosomaldominant auto-inflammatory condition characterised bytheclinical triadofarthritis, recurrent uveitis and granulomatous skin dermatitis; the absence of symptoms in the son's father therefore raised the suspicion that our patient had been misdiagnosed. NOD2 is the gene which has been implicated with 22 recorded mutations. NOD2 codes for a receptor involved in bacterial recognition and immune response. Of note, Blau syndrome shares an identical clinical phenotype with early onset sarcoidosis (EOS); these were initially felt to represent different disease entities but the advent of genetic testing has demonstrated that in fact they are the same disease. Some refer to Blau syndrome as the inherited form of the disease and EOS the sporadic form. Given our patient has no family history of inflammatory arthritis it is likely she has a sporadic mutation. Our patient underwent genetic testing, confirming that she had the same mutation as her son and thus supporting a change in her diagnosis. We prefer the terminology of Blau syndrome as an overarching diagnosis for our patient and her son, rather than EOS and Blaurespectively, as it clearly communicates the presence of a rare, genetically predetermined, paediatric polyarthritis. Discussion: Like the far more prevalent SJIA, Blau syndrome is a paediatric polyarthritiswithsystemic manifestations. Despite this overlap there are key differences that have been identified between the two with respect to both clinical findings and treatment strategies. Prevalence of uveitis in patients with Blau syndrome has been estimated to be 81%; this is far rarer in SJIA with only 0.6% of patients affected. Additionally in SJIA the posterior segment involvement, typified by choroidal scars, is never seen whereas it is found in 72% of Blau uveitis. Furthermore, uveitis in Blausyndrome is more likely to bebilateralthan JIA and morelikely to confer complications such as cataracts and visual impairment. Arthritis in Blau syndrome shows a symmetrical pattern involving both large and small joints. Classically florid, synovitis is exhibited at the joints with tenosynovitis and cysts frequently seen. Flexion deformities in the hands such as campylodactyly are common. Radiologically changes in Blau syndrome classically show no evidence of erosions. This contrasts with our patient whose radiographs have displayed progressive erosive damage; this discrepancy is explained by our patient having a rarer erosive form of Blau syndrome. There is no consensus regarding treatment for patients withBlausyndrome; theevidencesuggeststhatinflammationinBlausyndrome may persist despite combination use of steroids, immunosuppressive drugs and biologics. TNF alpha inhibition and IL-1 blockade, such as those received by our patient, have been seen anecdotally to partially control articular and ocular inflammation respectively. It seems therefore that our patient has been treated appropriately within the current body of evidence that is available, although establishing the diagnosis clearly has importance regarding disease phenotype. Critically had the patients true diagnosis been known, preconception planning with her would have included offering referral for genetic counselling to discuss the implications of having Blausyndrome. Key Learning Points: Blau syndrome is commonly misdiagnosed as SJIA. Consider the alternative diagnosis of Blau syndrome in patients displaying an autosomal dominant inheritance pattern of SJIA. Posterior segment uveitis is not seen in SJIA; its presence should prompt consideration of an alternative diagnosis. Although uncommon, joint erosions on radiology do not preclude a diagnosis of Blau syndrome. Genetic counselling services should be offered topatients with Blau syndrome. Disclosure: J.Ellis: None. B. Faber: None. S. Emerson: None. Introduction: Immunoglobulin G4-related disease (IgG4-RD) represents an immune-mediated fibro-inflammatory condition resulting in mass forming lesions with characteristic histopathological appearances. The disease can affect multiple different organs, with a range of clinical presentations to different medical and surgical specialties. Case description: We describe a case of a 71-year old female who presented with refractory facial pain following a dental procedure. She was treatedwithrepeated coursesofantibiotics bythedentistand wassubsequently referred for an ENT opinion. A CT scan revealed complete opacification of the left maxillary sinus with bony erosion of the floor, medial, anterior and posterior aspects of the maxillary antrum. Histological biopsies were reported as showing eosinophilic angiocentric fibrosis with an IgG4:IgG ratio of > 40%, consistent with a diagnosis of IgG4-RD. Peripheral blood IgG4 levels were normal and extended autoantibody screening, including ANCA, viral and TB screening were negative. Past medical history was significant for an unexplained episode of bronchus intermedius stenosis, ten years earlier. Thoracotomy yielded multiple biopsies which were reported at the time as showing non-specific granulomatous inflammation. Analysis of the historic samples revealed elevated levels of IgG4 staining. The patient was referred to rheumatology and commenced prednisolone 30mg orally with some improvement in facial pain. The dose was subsequently weaned to a maintenance dose of 7.5mg daily. Mycophenolate mofetil (MMF) was commenced as a steroid sparing agent (1 gram twice daily). Unfortunately, there was radiological evidence of disease progression with ongoing bone loss, despite this therapy and the decision was made in the IgG4-RD MDT, to proceed with Rituximabwithcyclophosphamide induction. Therehasbeensome resolution of the inflammatory changes and treatment is ongoing. Discussion: With an estimated incidence of 60m per million populations, IgG4-RD isarare, butincreasinglyrecognized condition.First linetherapy remains glucocorticoids. Rituximab has been commissioned by NHS Englandforuseinrefractoryororgan threatening IgG4-RD. Inthiscase rituximab has shown superiority to MMF in improving the symptoms and resolution of inflammation. Arguably the trial of MMF delayed the more effective treatment and resulted in more bony loss. The extent to which the addition of iv cyclophosphamide potentiated the effects Rituximab is not known and more research is needed. The episode of bronchus intermedius stenosis suffered almost a decade earlier, coupled with the multiple courses of antibiotics and delayed contemporary diagnosis, highlights the diagnostic challenges of IgG4-RD. Key Learning Points: Consider further review and IgG4 staining of any available previous histopathology samples if a diagnosis of IgG4-RD is made. Consider the addition of cyclophosphamide in organ threatening disease as an induction agent. Consider Rituximab early in organ threatening disease to preventprogression to irreversible damage. Disclosure: F.Osman: None. J.Vila: None. Rheumatology Department, University Hospital Wishaw, Wishaw, UNITED KINGDOM Introduction: Rheumatologists frequently manage patients with multisystem diseases. It is not uncommon for the diagnosis to be unclear initially, but in most cases the combination of clinical features, the course of the disease and targeted investigation confirms a diagnosis; allowing delivery of evidence-based treatments. However, there are some cases that donot fit arecognised disease pattern and inwhomextensive investigation may not identify a unifying diagnosis. We describe the complex case of a 28 year old female who initially presented in 2011 with symptoms related to a pleural effusion and who has since developed an increasing number of manifestations of an as yet undiagnosed multi-system inflammatory disorder. Consequently, she has been seen by numerous specialties and had extensive investigation undertaken throughout the years. She has also had trials of different immune modulating treatments with little effect. She has remained a diagnostic challenge and involvement of tertiary centres has been necessary. This case highlights the unusual clinical course of this illness, the various investigations and trials of therapy, and the many cross-site and inter-specialty discussions we have had regarding this patient. We hope this case highlights a rare clinical entity that may allow a discussion at conference to improve care of this patient and other patients with similar presentations. Case description: We present the case of LF, a 28 year old female with a past medical history of autism/Asperger's syndrome, bilateral sensorineural deafness, migraines. She has one relative with rheumatoid arthritis (mother) but no other significant family history. She initially presented in November 2011 at 22 years old with breathlessness, pleuritic chest pain and a large right pleural effusion. Empyema was suspected and she was treated with antibiotics and a chest drain. Sampling revealed an exudative effusion and microbiology was negative. At the time of chest drain insertion the pleura was notably thickened. She was allowed home but represented in March 2012 with bilateral pleural effusions. An echo excluded heart failure, and she was again treated with antibiotics and discharged. Following these initial admissions she has had recurrent presentations with problems arising from different organ systems and has had involvement from rheumatology, respiratory, gastroenterology, dermatology, infectious diseases, ophthalmology, genetics and neurology. The timeline of her problems from 2011 to date is summarised as follows: November 2011: initial presentation with right pleural effusion March 2012: bilateral pleural effusions April 2012: anterior uveitis, treated with i48 September 2018 CASE REPORTS
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